Cardiovascular Risk The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, found that testosterone replacement did not increase the rate of major adverse cardiovascular events in middle-aged and older men with hypogonadism and high cardiovascular risk (HR 1.02, 95% CI 0.84 to 1.24)
Why is Demand for Glutathione Supplements Growing
Much like any other disease state, if one type of therapy isnt feasible due to cost, access, tolerance, or just ineffectiveness for a specific patient, then pursuing an alternate treatment strategy is a very reasonable course of action, says Maselli
Secondary objectives were the demonstration of the superiority of tirzepatide for change in HbA1c, weight, and waist circumference
Other oral BPC-157 products vary in their testing documentation and company backgrounds